Compare Recursion Pharmaceuticals Inc (RXRX) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Recursion Pharmaceuticals Inc trades at $3.31 (market cap $1.81B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $242.49 (market cap $46.84B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 25.9× Recursion Pharmaceuticals Inc's market cap, and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | TTWO | |
|---|---|---|
Market Cap | $1.81B | $46.84B |
Sector | Health | Media |
52-Week High | $6.79 | $262.29 |
52-Week Low | $2.84 | $189.69 |
Enterprise Value | $1.33B | $47.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Take-Two Interactive (TTWO) trades at $253.57, up 2.87% on the day, with a bullish technical signal and strong analyst support. The stock shows robust earnings beats in recent quarters despite a net loss, driven by NBA 2K and Grand Theft Auto (GTA) performance. Cash flow improved in 2025 due to financing activities, while debt levels remain elevated. Investor focus centers on the November 2026 GTA VI launch, with preorders termed 'unprecedented' by management (Bloomberg, August 7, 2026).
The outlook hinges on GTA VI's success, offering substantial upside to the $300.55 consensus target, but execution risks and high valuation multiples (P/S 6.94, EV/EBITDA 38.35) warrant caution. Near-term volatility may persist amid earnings uncertainty, though institutional bullishness (78.95% buy ratings) underscores long-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
